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doi:10.101Human CD41CD251 Cells in Combination with CD341
Cells and Thymoglobulin to Prevent
Anti-hematopoietic Stem Cell T Cell Alloreactivity
Dolores Mahmud,1 Benedetta Nicolini,1 Lennert van den Dries,1 Nadim Mahmud,1,3
Mario Arpinati,2 Damiano Rondelli1,31 1 1 1Cotransplantation of human CD34 hematopoietic stem cells (HSC) and CD4 CD25 FoxP3 regulatory T
cells (Tregs) could prevent anti-HSC alloreactivity and reduce the risk of rejection in HLA mismatched
transplants. To pursue this hypothesis we cocultured CD341 cells and CD41CD251 cells immunomagneti-
cally isolated (Milteny) from human peripheral blood (unmanipulated or granulocyte-colony stimulating factor
[G-CSF] mobilized) or cord blood. Enriched Tregs obtained from the same source (autologous) of CD341
cells showed greater inhibitory effect on T cell alloreactivity than third-party (allogeneic) Tregs. The immuno-
suppressive activity of Tregs was maintained after stimulation with allogeneic CD341 cells and Tregs did not
modify the clonogenic activity of CD341 cells in vitro. Cotransplantation of Tregs with CD341 cells at 1:1 or
2:1 ratios in nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice resulted in normal
hematopoietic stem cell engraftment. Incubation with physiologic doses of rabbit antithymocyte globulin
(rATG, thymoglobulin) did not affect the number of Tregs in 6-day culture. Upon exposure to thymoglobulin
Tregs maintained their suppressive activity, increased expression of CCR7, and released multiple cytokines,
primarily interleukin (IL)10. Our findings suggest that human autologous or allogeneic Tregs could be cotrans-
planted with CD341 cells after preparative regimens including thymoglobulin.
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After allogeneic hematopoietic stem cell transplan-
tation (HSCT), graft rejection is more frequently asso-
ciated with transplantation of T cell-depleted grafts,
use of nonmyeloablative conditioning regimens, or use
of cord blood (CB) stem cells [1]. T cell depletion by
means of selection of CD341 cells has been utilized
particularly in transplants from HLA mismatched do-
nors to prevent graft-versus-host disease (GVHD) [2].
Rejection of CD341 cells can occur because of alloreac-
tive hostT cells. The allo-antigen presenting cell (APC)
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alloreactive T cells inducing the rapid upregulation
of costimulatory molecules [3-5]. In addition, the
crosstalk between CD341 cells and allo-T cells was
shown to induce the release of cytokines such as
tumor necrosis factor-alpha (TNF-a) and granulocyte
macrophage-colony stimulating factor (GM-CSF) by
T cells that contributed to a rapid (5 day) differentiation
of hematopoietic progenitors in CD11c1CD861 APC
[6]. Importantly, this CD34-derived APC subset
demonstrated potent allostimulatory effect by means
of direct, but also indirect antigen presenting capacity.
Strategies to prevent anti-HSC alloreactivity have
been investigated in thepast, suchas theuseofacostimu-
latory blockade [7], which resulted in antigen-specific T
cell unresponsiveness, or identification of nonimmuno-
genic subsets ofCD341 cells, such asCD182orCD402
progenitors [3-5]. However, none of these approaches
are yet available in clinical transplant settings. An
alternative strategy could be represented by the use of
immunosuppressive cells, such as mesenchymal cells
or regulatory T cells (Tregs) [8-10]. In particular,
Tregs are of great interest in the transplant setting as
a potential tool for inducing antigen-dependent T cell
unresponsiveness [11,12].61
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[13] or mismatched related donors [2], the use of
antithymocyte globulin (ATG) is associated with
reduced GVHD. Recent studies demonstrated that
rabbit ATG (thymoglobulin) spares and even expands
CD41CD251FoxP31 cells [14,15]. In this study, we
tested whether the combination of Tregs and CD341
cells can inhibit anti-stem cell alloreactivity while
preserving stem cell activity. In addition, we tested
whether Tregs’ inhibition of anti-stem cell T cell
alloreactivity would be affected by previous exposure to
thymoglobulin, in an attempt to mimic pretransplant
conditioning regimens including such agents.MATERIALS AND METHODS
Cell Separation
CB or peripheral blood (PB) mononuclear cells
(MNCs) and CD341 or CD31 cells were isolated as
previously described [6]. CD41CD251 or CD41
CD252 cells were immunomagnetically isolated from
unstimulated PB by a 2-step process including a CD4-
positive selection followed by aCD25-negative selection
using the Treg isolation kit (Miltenyi Biotec, Auburn,
CA) or by a 3-step process including an initial monocyte
depletion (CD14 separation kit, Miltenyi) when using
granulocyte-colony stimulating factor (G-CSF) mobi-
lized PB stem cells (PBSCs).
Flow Cytometry
Flow cytometric analysis was performed as previ-
ously described [6] using the following FITC, or PE,
or PerCP-conjugated monoclonal antibodies (mAbs):
CD34, CD3, CD4, CD25, CCR7, GITR, CD152,
and CD62L. An anti-FoxP3 PE mAb was utilized for
intracellular staining after permeabilization of the cell
membrane according to themanufacturer’s instruction
(eBioscience, San Diego, CA).
T Cell Proliferation
In vitro liquid cultures with isolated MNC or
purified CD41CD251 or CD41CD252 cells were
performed in thepresenceof rabbitATG(Thymoglobu-
lin, Genzyme, Cambridge, MA) at 100 mg/mL. Cells
were cultured inmedium containing RPMI-1640 (Cam-
brex, Baltimore, MD), 100 U/mL penicillin (Cambrex),
100 mg/mL streptomicin (Cambrex), and 10% AB
human serum (HS, Hyclone, Logan, UT) that was not
inactivated. Cultures were performed in round-
bottomed 96-well plates for 12 days at 37C in a 5%
CO2 humidified atmosphere. Daily T cell proliferation
was assessed by 3H-thymidine uptake. In selected exper-
iments, CD41CD251 or CD41CD252 cells were
cultured at 2.5  104 cells/100 mL with Thymoglobulin
at 10 or 100 mg/mL for 6 days. Cells were then washedand viable cells were analyzed by trypan-blue exclusion
assay.
Primary MLC
Irradiated stimulator (S) cells were mixed with re-
sponder (R) cells at 1:1 or 1:2 ratio for 6 days [6].
Purified CD31 and CD41CD251 or CD41CD252
cells were used as responders. In selected experiments,
MLC experiments were performed by adding thymo-
globulin at 50, 100, 300, or 500 mg/mL to the culture.
In these experiments, media contained 10%AB human
serum that had not been inactivated. Proliferation was
measured by 3H-thymidine-uptake assay and stimula-
tion index (SI) was calculated for each experiment as
previously described [6].
Suppression Experiments
CD41CD251 and CD41CD252 cells, either
freshly isolated or after stimulation with irradiated
CD341 cells at 1:1 ratio for 6 days, were added back
to a primary MLC at 1:1 ratio with R. In selected
experiments, CD41CD251, or CD41CD252 cells as
control, were incubated for 3 to 6 days with Thymo-
globulin (Genzyme) at 100 mg/mL inmedium contain-
ing noninactivated 10% human serum, and then added
back to an MLC. The percentage of stimulation or
suppression of T cell responses compared to the
original MLC was calculated based on the SI obtained
in each experiment.
CFU-C Assay
Purified CD341were mixed with CD41CD251 or
CD252 cells at 1:1 ratio for 24 hours and then were
plated in methylcellulose medium with cytokines
(StemCellTechnologies,Vancouver,Canada) [6].Col-
ony forming cells (CFU-C), including granulocyte-
macrophage CFU (CFU-GM), erythroid progenitors
(burst-forming unit-erythroid [BFU-E]), and CFU-
Mix were scored after 14 days of culture.
Cytokine Assay
CD341 cells (5  104 cells/well in 96-round bot-
tom plate) were mixed with allogeneic CD41CD251
cells at 1:1 ratio in liquid culture w/wo addition of thy-
moglobulin at 100 mg/mL for 3 days in media contain-
ing noninactivated human serum. Control experiments
included liquid cultures with Tregs and thymoglobu-
lin. Supernatants were harvested (100 mL/well 5 rep-
licate wells) and anticytokines antibodies bound to
microbeads were used in sandwich immunoassay to
measure the levels of interleukin (IL)-2, IL-4, IL-5,
IL-10, IL-12, IL-13, TNF-a, GM-CSF, interferon
(IFN)-g (Bio-Plex Cytokine assay, Bio-Rad, Hercules,
CA), and TGF-b (TGF-b Multiplex kit, R&D Sys-
tems, Minneapolis, MN) according to manufacturers’
instruction.
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Human CB purified CD341 cells (2 105/animal)
were mixed with allogeneic PB selected CD41CD251
cells at 1:0, 1:1, or 1:2 ratio and then transplanted into
sublethally irradiated (300 cGy) nonobese diabetic/se-
vere combined immunodeficiency (NOD/SCID) mice
as previously described [6]. Six weeks after transplant
total bone marrow (BM) cells were collected and ana-
lyzed to assess the engraftment of human CD451 cells
of myeloid, lymphoid, and erythroid lineages by flow
cytometry.
Statistical Analysis
t-Test analysis or analysis of variance (ANOVA)
test were used for statistical analysis.RESULTS
Anti-CD34 Cell Alloreactivity is Suppressed by
Autologous or Allogeneic Tregs
In this study, we tested the hypothesis of whether
humanTregsmay be considered as a potential adoptive
therapy in combination with purified HSCT. We ini-
tially separated human natural Tregs, defined as
CD41CD251 cells, from CB, PB, or PBSC by means
of a standard immunomagnetic method which is avail-
able also in clinical scale [16,17] and, therefore, could
be of potential clinical benefit. After separation,
CD41CD251 cell purity was on average 73% 6 9%
(n5 11 experiments) (Figure 1A). Purity rates of Tregs
obtained fromCB, PBSC, or PB were comparable (notFigure 1. Tregs isolation and effect on CD341 cell allostimulatory activity. (A
lation kit, Miltenyi) and (B) expression of CD25, CD127, and FoxP3 in CD41CD
(C) Tregs or CD41CD252 T cells isolated from allogeneic peripheral blood (
(AUTO PBSC) were added to an MLC with irradiated CD341 cells and a
CD41CD252 cell ratios were: 1:2 and 1:1, respectively (n 5 3 experiments
T cell responses and mean 6 SD cpm are shown (C, left). Addition of Treg
each condition (ALLO PB: P 5 .2; Auto CB: P 5 .05, Auto PBSC: P 5 .05). A
the same stem cell product as CD341 cells (AUTOCB or AUTO PBSC) had a g
is indicated by the percentage of inhibition of responder cells.shown). Expression of intracellular FoxP3 and dim ex-
pression of CD127 onCD41CD251 cells were consis-
tent with Treg phenotype (Figure 1B).
The function of these cells was then tested. Pri-
mary MLC were performed with irradiated CD341
cells isolated from CB or PBSC and allogeneic
CD31 responder cells isolated from unmanipulated
blood. Tregs or CD41CD252 control cells were iso-
lated from PB, CB, or PBSC and could be allogeneic
(PB) or autologous (CB or PBSC) to the CD341 cells.
PB Tregs allogeneic to CD341 cells (ALLO PB)
showed a 41% 6 16% inhibition of anti-CD341 cell
T cell alloreactivity in MLC, compared to autologous
CB Tregs (AUTO CB) (68% 6 14%) or autologous
PBSC (AUTO PBSC) Tregs (76% 6 16%) (P 5 .04)
(Figure 1C). As expected, in control experiments,
addition of CD41CD252 cells that were allogeneic
to CD341 stimulator cells and allo-responders in-
creased anti-CD34 alloreactivity (ALLO PB), whereas
when they had been isolated from the same source of
CD341 cells did not modify the proliferation of allo-
responders (AUTO CB, AUTO PBSC). To address
the concern that Treg purity after immunomagnetic
isolation was not sufficient and alloreactive T cells
would be present, we tested whether prior incubation
of the isolated Treg population with allostimulatory
CD341 cells could hamper the suppressive effect of
the cells by stimulating residual non-Treg T cells.
After coculture with irradiated CD341 cells for 6
days at 1:1 ratio, Tregs were added back to a primary
MLC with CD341 cells and third-party T cell re-
sponders. In Figure 2, we show that Tregs maintained) Purity of CD41CD251 cells after immunomagnetic isolation (Treg iso-
251 (filled histogram) or CD41CD252 (open histogram) cell fractions.
ALLO PB), or autologous cord blood (AUTO CB), or autologous PBSC
llo-responder T cells. CD34: allo-responder, and responder: Treg or
for each condition). 3H-thymidine uptake assay was utilized to measure
s resulted in reduced alloreactivity compared to CTR experiments in
nalysis of T cell inhibition (C, right) showed that Tregs obtained from
reater suppressive activity (P5.04 by ANOVA test). Suppression activity
Figure 2. Unmodified suppressive activity of Tregs primed with alloge-
neic CD341 cells. Allogeneic PB Tregs that were initially cultured with
irradiated CD341 cells for 6 days maintained their suppressive activity
when added to a third party MLC at a 1:1 ratio with responder cells,
as opposed to control CD41CD252 cells, which instead increased T
cell alloreactivity (n 5 3 experiments). The effect of Tregs or
CD41CD252 cells is shown as percentage (%) of T cell proliferation
or suppression compared with control MLC where allo-T cells are
stimulated by CD341 cells. Results are shown as average 6 SD of 3
separate experiments.
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sponses as much as seen when using freshly unstimu-
lated Tregs (Figure 1).Tregs Do Not Affect In-Vitro and In Vivo CD341
Cell Clonogenic Activity
We then tested whether Treg cells that have po-
tential clinical application may affect the stem cell
function of CD341 cells. The short-term clonogenic
activity of CD341 cells, measured as number of
granulo-monocytic (CFU-GM), erythroid (BFU-E),
or less committed mixed (CFU-Mix) colonies, was
not affected in a standard 2 weeks CFU-C assay after
initial 24 hours liquid culture of CD341 cells with
Tregs or CD41CD252 cells as control (Figure 3A).
To assess the long-term engraftment we cotrans-Figure 3. Clonogenic activity of CD341 cells in the presence of Tregs. (A) CD
and then tested for CFU-C in semisolid media (n5 5 experiments). Differences
were transplanted into NOD/SCID mice w/wo allogeneic Tregs at a 1:1 or 1:2
cytometry to assess human hematopoietic stem cell engraftment. The percenta
group). Analysis of subsets of huCD451 cells did not show differences in myeloplanted CD341 cells and Tregs at 2 different doses
in NOD/SCID mice. Similar to what was observed
in vitro, the in vivo engraftment of huCD341 cells
into NOD/SCID mice was not affected after cotrans-
planting CD341 cells and Tregs at 1:1 or 1:2 ratio
(Figure 3B). The percentage of myeloid cells, myeloid
DC, B cells, and erythroid cells was not different in the
2 groups compared to mice transplanted with CD341
cells alone (not shown).In Vitro Effect of Thymoglobulin on T Cells
Clinical transplantation of CD341 cells in an HLA
mismatch setting often includes the use of ATG in the
conditioning regimen as a means of in vivo T cell modu-
lation/depletion [2]. Based on ATG pharmacokinetics
[18,19], any adoptive T cell therapy should be avoided
for at least 2 weeks following treatment with ATG. A
dose of thymoglobulin at 7 mg/kg of an adult patient’s
body weight, often used in clinical trials, corresponds
approximately to a plasma concentration of 100 mg/mL,
and this physiologic dose was also tested in a previous
study [20]. We added doses of thymoglobulin from 50
to 500 mg/mL to MLC and assessed the effect on T cell
alloreactivity in vitro. Experiments were performed with
or without inactivation of complement in the media
with no different results. We observed an increased T
cell proliferation in primary MLC, where thymoglobulin
was added at 50, 100, or 300 mg/mL, whereas a high dose
of thymoglobulin at 500 mg/mL was highly suppressive
(Figure 4A). To test if this observation was because of
an antigen-independent direct effect of thymoglobulin
on T cells, we incubated T cells with thymoglobulin
at 100 mg/mL and measured T cell proliferation by
3H-thymidine uptake assay every day for 12 days. In 1
representative experiment of 3 separate performed, shown
in Figure 4B, thymoglobulin induced an initial prolifera-
tion of T cells, peaking on days 4 and 5, even when addi-
tional doses of thymoglobulin were added on days 3 and
6 of culture.341 cells were mixed with CD41CD251 or CD252 T cells at a 1:1 ratio
were not statistically significant by ANOVA test. (B) HumanCD341 cells
ratio, and 6 weeks later the marrow was harvested and tested by flow
ge of human CD451 cells was comparable in each group (n5 5 mice per
id or erythroid lineages in animals transplanted w/wo Tregs (not shown).
Figure 4. Effect of thymoglobulin on T cell proliferation in vitro. (A) Thymoglobulin was tested in vitro at 0 (control), 50, 100, 300, or 500 mg/mL, in
primary MLC with MNC stimulator cells and allogeneic T cell responders at a 1:2 ratio in media containing human AB serum that was not inactivated. T
cell alloreactivity was measured by 3H-thymidine incorporation assay after 6 days of culture. Results are shown as mean S.I. 6 SD of 5 separate exper-
iments. T cell alloresponses in the presence of thymoglobulin at 50, 100, or 300 mg/mL were greater than in control MLC (P 5 .02), whereas thymo-
globulin at 500 mg/mL completely inhibited T cell response (P 5 .03). (B) Thymoglobulin was added to liquid cultures of purified T cells at the
physiologic dose of 100 mg/mL on day 1 only (B, left), days 1 and 3 (B, center), or days 1, 3, and 6 (B, right). T cell proliferation was measured daily
for 12 days by 3H-thymidine incorporation assay, and cpm values of 1 experiment representative of 3 are shown.
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by Tregs Treated with Thymoglobulin
Based on the results earlier, we then tested whether
thymoglobulin would still permit Tregs to reduce
anti-CD34 cell alloreactivity. To this purpose, we ini-
tially incubated Tregs with thymoglobulin at 10 or
100 mg/mL for 3 or 6 days and then assessed cell viabil-
ity in culture. As shown in Figure 5A, the number of
Tregs did not significantly change over time compared
to the baseline number (shown as dotted line), with
a slight increase when a lower dose of thymoglobulin
was utilized. More importantly, stimulation with
thymoglobulin for 6 days did not modify the expres-
sion of FoxP3, whereas it increased the expression of
CCR7, GITR, and CD152 on Tregs (Figure 5B).
Finally, in experiments where allogeneic (third party)
CD41CD251 or CD41CD252 cells pretreated with
thymoglobulin for 3 days were added to a primary
MLCwith CD341 cells and alloreactive T cells, Tregs
maintained the capacity of inhibiting anti-HSC T-cell
alloreactivity as opposed to CD41CD252 control cells
that showed little effect on the allo-responders
(Figure 5C). Thymoglobulin effect on Tregs was sim-
ilar when these cells had been obtained from third
party PB or same PB as alloresponders (not show).
Thymoglobulin StimulatesTregs-Mediated IL-10
Production
To assess whether thymoglobulin would have any
effect on the interaction between Tregs and CD341
cells, we utilized a Th1/Th2 Bioplex Cytokine assay(Bio-Rad) and a TGF-bMultiplex kit (R&D Systems)
to measure the cytokine production after 3 days of co-
culture of CD341 cells and Tregs w/wo thymoglobu-
lin. In experiments with CD341 cells and Tregs
without thymoglobulin, almost undetectable levels of
cytokines were detected (Figure 6, left). On the con-
trary, in experiments where thymoglobulin was added
to Tregs and CD341 cells (Figure 6, center) or to
Tregs alone (Figure 6, right), an increased production
of cytokines, primarily IL-10, was observed. On the
contrary, no detectable levels of TGF-b were found
in any of the conditions described before (not shown).
In control experiments on media containing only thy-
moglobulin no cytokines were found (not shown).DISCUSSION
In this study, we show that an immunomagneti-
cally enriched Treg cell population combined with
CD341 hematopoietic progenitors permits an efficient
stem cell activity and inhibits the anti-stem cell
alloreactivity of HLA mismatched T cells even in the
presence of physiologic doses of thymoglobulin.
With an immunomagnetic cell separation method
(Miltenyi) available also in clinical scale [16,17], Treg
isolation required a 2-step process using unmanipulated
PB or CB and a 3-step process with PBSC, and resulted
in a purity of 73% on average. Selected Tregs expressed
CD25 at different intensity, but were shown to express
also FoxP3 and low levels of CD127. Our interest in
testing these cells with CD341 cells was based on
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Figure 5. Thymoglobulin does not affect Tregs in vitro . (A) Liquid cultures of CD41CD251 or CD41CD252 cells were performed in the presence of
thymoglobulin at 10 or 100 mg/mL. Dotted line represents the baseline number of cells plated. After 3 and 6 days of culture, cells were harvested and
counted by trypan blue exclusion to assess viable cells. Results are shown as average6 SD of 5 separate experiments. (B) Expression of CCR7, GITR,
CD152, CD62L, and intracytoplasmic FoxP3 before (Pre) and after a 3-day culture with thymoglobulin (Post-thymo) was analyzed by flow cytometry in
PB CD41CD251 Tregs. Histograms shown are representative of one of 3 separate experiments; (C) Allogeneic CD41CD251 cells, or CD41CD252
cells as control, were exposed to thymoglobulin for 3 days in vitro and then were added back to a primary MLC with irradiated CD341 stimulator cells
and third-party T cells (n5 3 experiments). Thymoglobulin-exposed Tregs (Thymo-CD41CD251) suppressed the anti-HSC T cell alloreactivity as op-
posed to thymoglobulin-exposed CD41CD252 cells. Suppression activity is indicated by the percentage of inhibition of responder cells.
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stimulate allogeneic T cell responses in vitro because of
a subset of these progenitors with potent ability of
presenting alloantigen and delivering costimulatory
signals to CD41 and CD81 T cells [3,4]. Particularly,
costimulatory molecules such as CD80, CD86, CD40,
or ICOS-Lare rapidly upregulated onCD341 cells in re-
sponse to T cell contact and/or in the presence of TNF-
a [5,21]. Futhermore, the allostimulatory activity of
CD341 cells can be greatly enhanced upon crosstalking
with allogeneic T cells that induce the differentiation of
progenitors into professional APC in vitro and in vivo
[6]. Here, we observed that Tregs obtained from the
same source of CD341 cells, that is, PBSC or CB,
suppressed anti-stem cell T cell alloreactivity by0 100 200 300 400 500
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Figure 6. Thymoglobulin-induced IL10 production by Tregs. CD41CD251 T
moglobulin at 100 mg/mL, or with thymoglobulin alone. After 3 days supernata
tokine assay (n5 3 experiments). In the presence of thymoglobulin, Tregs prod
CD341 cells.approximately 70%. The potent inhibitory effect de-
tected despite a nonhighly purified Treg cell population
is likely to be because of the fact that bystander residual
non-Tregs were autologous to CD341 stimulator cells.
However, third-party Tregs also inhibited T cell allores-
ponses by appoximately 40% to 50%, suggesting that
residual bystander non-Tregs had very limited or no re-
sponse capacity and did not prevent the Tregs from in-
hibiting allo-responders in MLC. This could be
explained by a low sensitivity of the assay in measuring
T cell proliferation. Alternatively, Tregs could induce
the apoptosis of bystander CD4 effectors, as recently re-
ported [22]. In a clinical setting, these findings suggest
that a Treg product enriched in CD41CD251 cells
would not increase the risk of GVHD. Moreover, the300 400 500
D34/Tregs/thymo
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regs were cultured with CD341 cells at a 1:1 ratio, with CD34 and thy-
nts were harvested and cytokine levels were measured by Bio-Plex Cy-
uced mostly IL-10 and IL-13 independently of the allostimulatory effect of
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cells could have the advantage of facilitating the immune
reconstitution posttransplant. This effect, in fact, was
demonstrated in a mouse model where Tregs improved
the development of lymphoid cells derived from the graft
by reducing GVHD, preserving thymic and lymph node
structure, and accelerating the reconstitution of a diverse
TCR-Vb repertoire [23].
In ourmodel, humanTregs did not affect the clono-
genic activity of CD341 cells measured by CFU-C in
vitro and BM engraftment after transplantation in
NOD/SCID mice. In a recent study, Urbieta et al.
[24] utilized BALB/C and B6 mice to test the effect of
Tregs on hematopoiesis and found that Tregs activated
with anti-CD3/CD28 beads and IL2 released TGF-
b and suppressed CFU IL3/SCF in vitro and affected
the recovery of neutrophils after T cell-depleted BM
transplantation. This inhibitory effect was not observed
when using freshly isolated Tregs. Although we did not
test the effect of Tregs after in vitro activation with
CD3/CD28 beads, our study seems to have some differ-
ences compared to the previously mentioned one. We
used human Tregs with selected CD341 cells that
were previously shown to potently stimulate CD28 re-
ceptor on T cells through CD80 and CD86. When we
measured the production of cytokines in cultures of
CD341 and Tregs, we could not detect any cytokines
other than traces of TNF-a and IFN-g, but no TGF-
b. In addition, whenCD341 cells andTregs were trans-
planted in sublethally irradiated NOD/SCID mice, we
assumed that Tregs would find multiple cytokines
released by tissues upon radiation and by host cells.
Nevertheless, Tregs did not affect the stem cell engraft-
ment when tested at 2 different doses. We assume,
therefore, that the clinical role of human Tregs in
CD341 cells transplantation remains to be found, and
it can be investigated in experimental clinical trials.
Because in HLAmismatched or haploidentical SCT
the addition of ATG in the conditioning regimen is clin-
ically relevant to reduce the risk ofGVHD fromdonorT
cells, and likely reduces the risk of rejection from host T
cells, we addressed the question whether physiological
doses of rATG (thymoglobulin) would affect the func-
tion of Tregs added to alloreactive T cells and CD341
cells. Indeed, recent studies proposed that thymoglobulin
can expand Tregs by increasing the expression of FoxP3
not only on CD41CD251 but also on CD41CD252
cells, therefore increasing the pool ofCD41 cells with in-
hibitory function [14,15]. Our approach differed from
previous studies. We initially found that physiologic
doses of thymoglobulin stimulated the proliferation in
vitro of T cells within the first 3 to 5 days of culture.
The mechanism for this finding remains uncertain,
although it could be explained by recent findings
showing high levels of type 1 and 2 cytokines released
by CD41 cells stimulated with thymoglobulin [25]. In
our experiments where thymoglobulin was tested in vitrofor 6 days on purifiedTcell subsets, we observed the pro-
liferation of CD41CD252 and CD81 cell fractions (not
shown) but not of CD41CD251Tregs, which remained
unchanged compared to baseline numbers. However,
Tregs that were cultured with thymoglobulin increased
the expression of CD152 (CTLA4) andmaintained their
inhibitory effect on anti-stem cell T cell alloreactivity. In
contrast, CD41CD252 cells showed only a very weak
upregulation of FoxP3 (not shown) and no suppressive
activity when added to allogeneic MLC.
A previous study suggested that among other im-
munologic effects, thymoglobulin can also reduce the
chemotaxis of CD41 T cells to tissues with increased
antigen presentation by blocking the binding of
CXCR4 and SDF1 [20]. We observed an increased ex-
pression of CCR7 on isolated Tregs upon stimulation
with thymoglobulin. CCR7 was previously shown to
play a key role on the trafficking of naı¨ve or central
memory-like Tregs [26]. We, therefore, hypothesize
that another immunomodulatory effect of thymoglo-
bulin may be mediated by increasing the recirculation
of Tregs in different tissues or lymphoid organs after
transplantation. Our findings support other studies
suggesting that thymoglobulin affects immune re-
sponses, at least initially, by an immunomodulatory
rather than a cytotoxic effect. In fact, we demonstrated
a direct effect of thymoglobulin on Treg ability to re-
lease multiple cytokines and particularly IL-10, IL-5,
and IL-13, but not TGF-b. Importantly, this effect
of thymoglobulin was observed also when Tregs
were cocultured with allogeneic CD341 cells.
Overall, these results suggest that transplantation of
CD341 cells and Tregs from the same donor might
facilitate the engraftment by reducing the anti-stem
cell response of host T cells. A direct effect of Tregs
on donor T cells reducing GVHDwould also be bene-
ficial for a faster immune reconstitution [23]. Because
the in vivo suppressive effect of expanded/induced
Tregs remains unclear [27], the use of PBSC as a source
of natural Tregs will facilitate the design of new clinical
strategies of cotransplantation of CD341 and Tregs in
T cell-depleted stem cell transplantation, as recently
proposed [28] in a haploidentical transplantation study.
Based on the effects of thymoglobulin on Tregs shown
here, it could be also speculated that addition of Tregs
to unmanipulated grafts in the presence of thymoglobu-
lin may further enhance the anti-GVHD activity.
However, this hypothesis is difficult to be tested in vitro
and can only be validated in clinical trials.ACKNOWLEDGMENTS
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